Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nephros (NEPH) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Nephros (NEPH) over the last 17 years, with Q3 2025 value amounting to $380000.0.

  • Nephros' Change in Accured Expenses rose 43928.57% to $380000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $901000.0, marking a year-over-year increase of 33161.95%. This contributed to the annual value of -$226000.0 for FY2024, which is 14466.4% down from last year.
  • Per Nephros' latest filing, its Change in Accured Expenses stood at $380000.0 for Q3 2025, which was up 43928.57% from $168000.0 recorded in Q2 2025.
  • Nephros' 5-year Change in Accured Expenses high stood at $380000.0 for Q3 2025, and its period low was -$380000.0 during Q1 2024.
  • Its 5-year average for Change in Accured Expenses is $55842.1, with a median of $98000.0 in 2023.
  • As far as peak fluctuations go, Nephros' Change in Accured Expenses plummeted by 48775.51% in 2024, and later skyrocketed by 66363.64% in 2025.
  • Nephros' Change in Accured Expenses (Quarter) stood at -$128000.0 in 2021, then skyrocketed by 118.75% to $24000.0 in 2022, then soared by 237.5% to $81000.0 in 2023, then skyrocketed by 201.23% to $244000.0 in 2024, then skyrocketed by 55.74% to $380000.0 in 2025.
  • Its Change in Accured Expenses stands at $380000.0 for Q3 2025, versus $168000.0 for Q2 2025 and $109000.0 for Q1 2025.